<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401555</url>
  </required_header>
  <id_info>
    <org_study_id>RP.BVD.GEHIV.02</org_study_id>
    <nct_id>NCT02401555</nct_id>
  </id_info>
  <brief_title>Performance Evaluation of the Bio-Rad Geenius HIV1/2 Supplemental Assay</brief_title>
  <official_title>Performance Evaluation of the Bio-Rad Geenius HIV1/2 Supplemental Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bio-Rad Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bio-Rad Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the performance of the Bio-Rad Geenius HIV 1/2
      Supplemental Assay, a single-use immunochromatographic assay for the confirmation and
      differentiation of individual antibodies to Human Immunodeficiency Virus Types 1 and 2 (HIV-1
      and HIV-2) in fingerstick whole blood, venous whole blood, serum, or plasma samples (EDTA,
      heparin, and sodium citrate).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospectively collected matched sample types, including fingerstick (capillary blood), serum,
      plasma, and whole venous blood were obtained from subjects at three clinical trial sites
      within the United States. Informed consent was used to enroll subjects at low risk for HIV
      (N=120 subjects) and from subjects pre-diagnosed as HIV positive (N=299 subjects).

      The fingerstick samples were tested with Geenius HIV 1/2 Supplemental Assay at the collection
      site, while the remaining matched sample types, (serum, plasma, and whole venous blood) were
      sent to a clinical lab to be tested on the Geenius HIV 1/2 Supplemental Assay. Results of the
      Geenius HIV 1/2 Supplemental Assay on each of 4 matched sample were compared to the serum
      result on the Bio-Rad GS HIV 1/HIV 2 PLUS O EIA, Bio-Rad HIV-1 Western blot, and the Bio-Rad
      Multispot HIV 1/HIV-2 Rapid Test (reference methods).

      Retrospective specimens from repositories or specimens purchased from commercial vendors were
      also included in the study. In addition to the Geenius HIV 1/2 Supplemental Assay, the GS HIV
      1/HIV 2 PLUS O EIA, Bio-Rad HIV-1 Western blot, and the Bio-Rad Multispot HIV 1/HIV-2 Rapid
      Test were utilized as reference methods. Historical data, when available, was also used. All
      samples were identified with a unique study number and included the following
      populations/panels:

        1. HIV-1/HIV-2 False Reactive Samples (N=100)

        2. Unrelated Medical Conditions (N=40).

        3. Normal Pediatric Patients (N=10)

        4. HIV-1 Positive Pediatric Patients (N=40)

        5. HIV-1 Non B Group M Subtypes (N=136)

        6. HIV-1 Group O Antibody Positive (N=15)

        7. Known HIV-2 Positive Population (N=200)

        8. HIV Performance Panels

             1. Anti-HIV-1/2 Combo Performance Panel: PRZ208 (N=15)

             2. HIV-1 Low Titer Panel: PRB109 (N=20)

             3. HIV-1 Incidence / Prevalence Panel: PRB601 (N=15)

             4. HIV-1 Seroconversion Panels (26 Panels, N=230)

        9. CEPHIA Evaluation Panel (N=2500)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic Result of Assay (Bio-Rad Geenius HIV 1/2 Supplemental Assay) From Accuracy Analysis</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>The purpose of this study was to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay, a single-use immunochromatographic assay for the confirmation and differentiation of individual antibodies to Human Immunodeficiency Virus Types1 and 2 (HIV-1 and HIV-2) in fingerstick whole blood, venous whole blood, serum, or plasma (EDTA, heparin and sodium citrate). The Accuracy analysis on the serum samples is a proportion of results that are correctly identified as such.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">419</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Known HIV1 positives</arm_group_label>
    <description>Individuals known to the HIV1 positive tested with Geenius HIV1/2 Supplemental Assay</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Known AIDS</arm_group_label>
    <description>Individuals known to meet diagnostic criteria for AIDS tested with Geenius HIV1/2 Supplemental Assay</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low risk (negatives)</arm_group_label>
    <description>Individuals at low risk for HIV infection tested with Geenius HIV1/2 Supplemental Assay</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Geenius HIV1/2 Supplemental Assay</intervention_name>
    <description>The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).</description>
    <arm_group_label>Known HIV1 positives</arm_group_label>
    <arm_group_label>Known AIDS</arm_group_label>
    <arm_group_label>Low risk (negatives)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV1 Positives: Individuals with confirmed HIV1 positive records AIDS Positives:
        Individuals with proved CDC stage 3 (AIDS) Low Risk patients: Low Risk individuals
        including potential military recruits, soldiers and civilians who have not reported any
        high risk behavior for HIV infection.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for HIV1 positives and AIDS positive populations:

          -  Should be able to provide informed consent.

          -  Must be greater than or equal to 18 years of age.

          -  Agree to provide a finger stick sample.

          -  Agree to provide upto 20 mL of blood by veni-puncture.

          -  Must have sufficient medical history to provide data required for the case report
             form.

        Exclusion Criteria for HIV1 positives and AIDS positive populations:

          -  Unable to provide informed consent

          -  Subjects who have received an experimental vaccine for HIV.

          -  Individuals except AIDS patients who are currently on ARV therapy with the duration
             from the start of therapy for more than 6 months.

        Inclusion Criteria for Low Risk population:

          -  Able to provide Informed consent

          -  Must be greater than or equal to 18 years of age.

          -  Subject does not report any high risk behaviors for HIV infection.

          -  Of unknown HIV status.

        Exclusion criteria for Low Risk Population:

          -  Unable to provide informed consent.

          -  Individuals with one or more high risk behaviors with HIV infection within the
             previous 6 months.

          -  Self reported history of HIV infection

          -  Prior receipt of HIV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Dennis, BS</last_name>
    <role>Study Director</role>
    <affiliation>Bio-Rad Laboratories</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HIV/AIDS Division, San Fransisco General Hospital</name>
      <address>
        <city>San Fransisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood Systems Research Institute</name>
      <address>
        <city>San Fransisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Disease Control and Prevention</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30333</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Center, Walter Reed Army Institute of Research</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Washington AIDS Clinical Trials Unit, Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104-2499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Delmonico FL, Snydman DR. Organ donor screening for infectious diseases: review of practice and implications for transplantation. Transplantation. 1998 Mar 15;65(5):603-10. Review.</citation>
    <PMID>9521191</PMID>
  </reference>
  <reference>
    <citation>Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vézinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983 May 20;220(4599):868-71.</citation>
    <PMID>6189183</PMID>
  </reference>
  <reference>
    <citation>Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, Palker TJ, Redfield R, Oleske J, Safai B, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984 May 4;224(4648):500-3.</citation>
    <PMID>6200936</PMID>
  </reference>
  <reference>
    <citation>Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, Temin H, Toyoshima K, Varmus H, Vogt P, et al. What to call the AIDS virus? Nature. 1986 May 1-7;321(6065):10.</citation>
    <PMID>3010128</PMID>
  </reference>
  <reference>
    <citation>Clavel F, Guétard D, Brun-Vézinet F, Chamaret S, Rey MA, Santos-Ferreira MO, Laurent AG, Dauguet C, Katlama C, Rouzioux C, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science. 1986 Jul 18;233(4761):343-6.</citation>
    <PMID>2425430</PMID>
  </reference>
  <reference>
    <citation>Clavel F, Mansinho K, Chamaret S, Guetard D, Favier V, Nina J, Santos-Ferreira MO, Champalimaud JL, Montagnier L. Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl J Med. 1987 May 7;316(19):1180-5.</citation>
    <PMID>3472076</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control (CDC). AIDS due to HIV-2 infection--New Jersey. MMWR Morb Mortal Wkly Rep. 1988 Jan 29;37(3):33-5.</citation>
    <PMID>3122008</PMID>
  </reference>
  <reference>
    <citation>O'Brien TR, George JR, Holmberg SD. Human immunodeficiency virus type 2 infection in the United States. Epidemiology, diagnosis, and public health implications. JAMA. 1992 May 27;267(20):2775-9.</citation>
    <PMID>1578597</PMID>
  </reference>
  <reference>
    <citation>Sullivan MT, Guido EA, Metler RP, Schable CA, Williams AE, Stramer SL. Identification and characterization of an HIV-2 antibody-positive blood donor in the United States. Transfusion. 1998 Feb;38(2):189-93.</citation>
    <PMID>9531953</PMID>
  </reference>
  <reference>
    <citation>Brun-Vezinet F, Rey MA, Katlama C, Girard PM, Roulot D, Yeni P, Lenoble L, Clavel F, Alizon M, Gadelle S, et al. Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Clinical and virological features in four patients. Lancet. 1987 Jan 17;1(8525):128-32.</citation>
    <PMID>2879971</PMID>
  </reference>
  <reference>
    <citation>Quinn TC, Zacarias FR, St John RK. AIDS in the Americas: an emerging public health crises. N Engl J Med. 1989 Apr 13;320(15):1005-7.</citation>
    <PMID>2467206</PMID>
  </reference>
  <reference>
    <citation>Guyader M, Emerman M, Sonigo P, Clavel F, Montagnier L, Alizon M. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature. 1987 Apr 16-22;326(6114):662-9.</citation>
    <PMID>3031510</PMID>
  </reference>
  <reference>
    <citation>Janssens W, Buvé A, Nkengasong JN. The puzzle of HIV-1 subtypes in Africa. AIDS. 1997 May;11(6):705-12. Review.</citation>
    <PMID>9143601</PMID>
  </reference>
  <reference>
    <citation>Charneau P, Borman AM, Quillent C, Guétard D, Chamaret S, Cohen J, Rémy G, Montagnier L, Clavel F. Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group. Virology. 1994 Nov 15;205(1):247-53.</citation>
    <PMID>7975221</PMID>
  </reference>
  <reference>
    <citation>Simon F, Mauclère P, Roques P, Loussert-Ajaka I, Müller-Trutwin MC, Saragosti S, Georges-Courbot MC, Barré-Sinoussi F, Brun-Vézinet F. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med. 1998 Sep;4(9):1032-7.</citation>
    <PMID>9734396</PMID>
  </reference>
  <reference>
    <citation>Meloni ST, Kim B, Sankalé JL, Hamel DJ, Tovanabutra S, Mboup S, McCutchan FE, Kanki PJ. Distinct human immunodeficiency virus type 1 subtype A virus circulating in West Africa: sub-subtype A3. J Virol. 2004 Nov;78(22):12438-45.</citation>
    <PMID>15507630</PMID>
  </reference>
  <reference>
    <citation>Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemée V, Damond F, Robertson DL, Simon F. A new human immunodeficiency virus derived from gorillas. Nat Med. 2009 Aug;15(8):871-2. doi: 10.1038/nm.2016. Epub 2009 Aug 2.</citation>
    <PMID>19648927</PMID>
  </reference>
  <reference>
    <citation>Gao F, Yue L, Robertson DL, Hill SC, Hui H, Biggar RJ, Neequaye AE, Whelan TM, Ho DD, Shaw GM, et al. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol. 1994 Nov;68(11):7433-47.</citation>
    <PMID>7933127</PMID>
  </reference>
  <reference>
    <citation>George JR, Rayfield MA, Phillips S, Heyward WL, Krebs JW, Odehouri K, Soudre R, De Cock KM, Schochetman G. Efficacies of US Food and Drug Administration-licensed HIV-1-screening enzyme immunoassays for detecting antibodies to HIV-2. AIDS. 1990 Apr;4(4):321-6.</citation>
    <PMID>2350452</PMID>
  </reference>
  <reference>
    <citation>Loussert-Ajaka I, Ly TD, Chaix ML, Ingrand D, Saragosti S, Couroucé AM, Brun-Vézinet F, Simon F. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet. 1994 Jun 4;343(8910):1393-4.</citation>
    <PMID>7910884</PMID>
  </reference>
  <reference>
    <citation>Schable C, Zekeng L, Pau CP, Hu D, Kaptue L, Gurtler L, Dondero T, Tsague JM, Schochetman G, Jaffe H, et al. Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections. Lancet. 1994 Nov 12;344(8933):1333-4.</citation>
    <PMID>7968029</PMID>
  </reference>
  <reference>
    <citation>Resnick L, Veren K, Salahuddin SZ, Tondreau S, Markham PD. Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments. JAMA. 1986 Apr 11;255(14):1887-91.</citation>
    <PMID>2419594</PMID>
  </reference>
  <reference>
    <citation>Bond WW, Favero MS, Petersen NJ, Ebert JW. Inactivation of hepatitis B virus by intermediate-to-high-level disinfectant chemicals. J Clin Microbiol. 1983 Sep;18(3):535-8.</citation>
    <PMID>6630443</PMID>
  </reference>
  <reference>
    <citation>Sehulster LM, Hollinger FB, Dreesman GR, Melnick JL. Immunological and biophysical alteration of hepatitis B virus antigens by sodium hypochlorite disinfection. Appl Environ Microbiol. 1981 Nov;42(5):762-7.</citation>
    <PMID>7316505</PMID>
  </reference>
  <reference>
    <citation>Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS; U.S. Public Health Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2005 Sep 30;54(RR-9):1-17.</citation>
    <PMID>16195697</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2015</study_first_posted>
  <results_first_submitted>November 24, 2015</results_first_submitted>
  <results_first_submitted_qc>February 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 28, 2017</results_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Known HIV1 Positives</title>
          <description>Individuals known to the HIV1 positive tested with Geenius HIV1/2 Supplemental Assay
Geenius HIV1/2 Supplemental Assay: The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).</description>
        </group>
        <group group_id="P2">
          <title>Known AIDS</title>
          <description>Individuals known to meet diagnostic criteria for AIDS tested with Geenius HIV1/2 Supplemental Assay
Geenius HIV1/2 Supplemental Assay: The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).</description>
        </group>
        <group group_id="P3">
          <title>Low Risk (Negatives)</title>
          <description>Individuals at low risk for HIV infection tested with Geenius HIV1/2 Supplemental Assay
Geenius HIV1/2 Supplemental Assay: The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="212"/>
                <participants group_id="P3" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="212"/>
                <participants group_id="P3" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Known HIV1 Positives</title>
          <description>Individuals known to the HIV1 positive tested with Geenius HIV1/2 Supplemental Assay
Geenius HIV1/2 Supplemental Assay: The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).</description>
        </group>
        <group group_id="B2">
          <title>Known AIDS</title>
          <description>Individuals known to meet diagnostic criteria for AIDS tested with Geenius HIV1/2 Supplemental Assay
Geenius HIV1/2 Supplemental Assay: The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).</description>
        </group>
        <group group_id="B3">
          <title>Low Risk (Negatives)</title>
          <description>Individuals at low risk for HIV infection tested with Geenius HIV1/2 Supplemental Assay
Geenius HIV1/2 Supplemental Assay: The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
            <count group_id="B2" value="212"/>
            <count group_id="B3" value="120"/>
            <count group_id="B4" value="419"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="406"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="220"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Result of Assay (Bio-Rad Geenius HIV 1/2 Supplemental Assay) From Accuracy Analysis</title>
        <description>The purpose of this study was to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay, a single-use immunochromatographic assay for the confirmation and differentiation of individual antibodies to Human Immunodeficiency Virus Types1 and 2 (HIV-1 and HIV-2) in fingerstick whole blood, venous whole blood, serum, or plasma (EDTA, heparin and sodium citrate). The Accuracy analysis on the serum samples is a proportion of results that are correctly identified as such.</description>
        <time_frame>Up to 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Known HIV1 Positives</title>
            <description>Individuals known to the HIV1 positive tested with Geenius HIV1/2 Supplemental Assay
Geenius HIV1/2 Supplemental Assay: The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).</description>
          </group>
          <group group_id="O2">
            <title>Known AIDS</title>
            <description>Individuals known to meet diagnostic criteria for AIDS tested with Geenius HIV1/2 Supplemental Assay
Geenius HIV1/2 Supplemental Assay: The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).</description>
          </group>
          <group group_id="O3">
            <title>Low Risk (Negatives)</title>
            <description>Individuals at low risk for HIV infection tested with Geenius HIV1/2 Supplemental Assay
Geenius HIV1/2 Supplemental Assay: The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Result of Assay (Bio-Rad Geenius HIV 1/2 Supplemental Assay) From Accuracy Analysis</title>
          <description>The purpose of this study was to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay, a single-use immunochromatographic assay for the confirmation and differentiation of individual antibodies to Human Immunodeficiency Virus Types1 and 2 (HIV-1 and HIV-2) in fingerstick whole blood, venous whole blood, serum, or plasma (EDTA, heparin and sodium citrate). The Accuracy analysis on the serum samples is a proportion of results that are correctly identified as such.</description>
          <units>Percentage of True Results</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95.76" upper_limit="100"/>
                    <measurement group_id="O2" value="99.06" lower_limit="96.62" upper_limit="99.74"/>
                    <measurement group_id="O3" value="95.83" lower_limit="90.61" upper_limit="98.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The period in which adverse event data were collected was 1 year (April 2013- April 2014).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Known HIV1 Positives</title>
          <description>Individuals known to the HIV1 positive tested with Geenius HIV1/2 Supplemental Assay
Geenius HIV1/2 Supplemental Assay: The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).</description>
        </group>
        <group group_id="E2">
          <title>Known AIDS</title>
          <description>Individuals known to meet diagnostic criteria for AIDS tested with Geenius HIV1/2 Supplemental Assay
Geenius HIV1/2 Supplemental Assay: The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).</description>
        </group>
        <group group_id="E3">
          <title>Low Risk (Negatives)</title>
          <description>Individuals at low risk for HIV infection tested with Geenius HIV1/2 Supplemental Assay
Geenius HIV1/2 Supplemental Assay: The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a five year period from the time of the non-disclosure agreement execution.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Bhend</name_or_title>
      <organization>Bio-Rad Laboratories</organization>
      <phone>425 498 1758</phone>
      <email>david_bhend@bio-rad.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

